Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 18Active not recruiting 17Completed 6Not yet recruiting 5Terminated 2Withdrawn 1Suspended 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Doxorubicin 4Cetuximab 4durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Platinum 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × selinexor × 1 year × Clear all
NCT04661137 2026-02-10

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Hackensack Meridian Health

Phase 2 Suspended
96 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡